These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38654484)

  • 1. Hepatic Dysfunction Quantified by HepQuant DuO Outperforms Child-Pugh Classification in Predicting the Pharmacokinetics of Ampreloxetine.
    Kanodia J; Giovinazzo H; Yates W; Bourdet DL; McRae MP; Helmke SM; Everson GT
    Clin Pharmacol Ther; 2024 Jul; 116(1):186-193. PubMed ID: 38654484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing hepatic impairment in Fontan-associated liver disease using the HepQuant SHUNT test.
    Lemmer A; VanWagner L; Gasanova Z; Helmke S; Everson GT; Ganger D
    Congenit Heart Dis; 2019 Nov; 14(6):978-986. PubMed ID: 31369200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology.
    Burton JR; Helmke S; Lauriski S; Kittelson J; Everson GT
    Transl Res; 2021 Jul; 233():5-15. PubMed ID: 33400995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic improvement within 27 days of avenciguat treatment in Child-Pugh A cirrhosis detected by an oral cholate challenge test.
    Lawitz EJ; Ertle J; Schoelch C; Gashaw I; McRae MP; Helmke SM; Everson GT
    Liver Transpl; 2024 Oct; 30(10):982-990. PubMed ID: 38869987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Within-individual reproducibility of a dual sample oral cholate challenge test (DuO) and simplified versions of the HepQuant SHUNT test.
    McRae MP; Kittelson J; Helmke SM; Everson GT
    Clin Transl Sci; 2024 Apr; 17(4):e13786. PubMed ID: 38558534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver function and portal-systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices.
    Hassanein T; Keaveny AP; Mantry P; Smith AD; McRae MP; Kittelson J; Helmke S; Everson GT;
    Aliment Pharmacol Ther; 2024 Jul; 60(2):246-256. PubMed ID: 38778481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in noninvasive measurement of liver function and physiology: The HepQuant DuO test.
    McRae MP; Kittelson J; Helmke SM; Everson GT
    Basic Clin Pharmacol Toxicol; 2024 Mar; 134(3):385-395. PubMed ID: 38225212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asenapine pharmacokinetics in hepatic and renal impairment.
    Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
    Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
    Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment.
    Marzin K; Kretschmar G; Luedtke D; Kraemer S; Kuelzer R; Schlenker-Herceg R; Schmid U; Schnell D; Dallinger C
    J Clin Pharmacol; 2018 Mar; 58(3):357-363. PubMed ID: 29106740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Compartmental model describing the physiological basis for the HepQuant SHUNT test.
    McRae MP; Helmke SM; Burton JR; Everson GT
    Transl Res; 2023 Feb; 252():53-63. PubMed ID: 35948199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment.
    Hoover R; Marbury TC; Preston RA; Quintas M; Lawrence LE; Paulson SK; Luke DR; Cammarata SK
    J Clin Pharmacol; 2017 Mar; 57(3):328-335. PubMed ID: 27570245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
    Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
    Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment.
    Grasela DM; Christofalo B; Kollia GD; Duncan G; Noveck R; Manning JA; LaCreta FP
    Pharmacotherapy; 2000 Jun; 20(6 Pt 2):87S-94S. PubMed ID: 10850525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of hepatic or renal impairment on the pharmacokinetics of edivoxetine, a selective norepinephrine transporter reuptake inhibitor.
    Kielbasa W; Tesfaye E; Luffer-Atlas D; Mitchell MI; Turik MA
    Eur J Clin Pharmacol; 2013 Dec; 69(12):2011-9. PubMed ID: 23955175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.
    Berger B; Dingemanse J; Sabattini G; Delahaye S; Duthaler U; Muehlan C; Krähenbühl S
    Clin Pharmacokinet; 2021 Oct; 60(10):1349-1360. PubMed ID: 34002356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
    Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
    Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
    Graff J; Harder S
    Clin Pharmacokinet; 2013 Apr; 52(4):243-54. PubMed ID: 23389892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment.
    Preston RA; Marbury T; Balaratnam G; Green M; Dixon S; Lehrer-Graiwer J; Washington C
    J Clin Pharmacol; 2021 Apr; 61(4):493-505. PubMed ID: 33084052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.